Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.
The termination ends a cardiometabolic RNA-editing partnership that was paused for 12 months, closing out a deal under which Korro earned no milestone payments.
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.